Navigation Links
BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
Date:10/28/2008

us T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
2. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
3. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
4. LCA-Vision Reports Third Quarter 2008 Financial Results
5. Universal Health Services, Inc. Reports 2008 Third Quarter Results
6. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
7. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
8. WellPoint Reports Third Quarter 2008 Results
9. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
10. Schering-Plough Reports Financial Results for Third Quarter of 2008
11. Quest Diagnostics Reports Growth in Revenue and Earnings for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Orem, UT—Dymicron, Inc., (dymicron.com) ... using their unique Triadyme-C cervical total disc replacement device. ... William D. Smith at the American Institute of Minimally ... are responding well to the implantation of the Dymicron ... Spine Center and Chief of Neurosurgery for the University ...
(Date:5/28/2015)... Omaha, NE (PRWEB) May 28, 2015 ... healthcare staffing, including nurse practitioner jobs, has announced that ... Association of Nurse Practitioners’ 2015 National Conference to be ... , AANP offers educational programming, networking opportunities, and ... Aureus Medical’s Advanced Practice division will be ...
(Date:5/28/2015)... 2015 Peggy J. Lynam, PT, DPT, NCS ... American Physical Therapy Association House of Delegates for the New ... Delegate Assembly. This will be her second term. ... coordinator and principle spokesperson for the Chapter delegation and presides ... or Delegate Assembly may direct the Chief Delegate to present ...
(Date:5/27/2015)... Gravity and volume loss in the skin have ... Holly CaSaroll, is excited to introduce a custom menu ... face, without surgical intervention, and without downtime. , “We ... approved procedure that can lift skin using focused ultrasound, ... new more lifting formula than its predecessor Radiesse, to ...
(Date:5/27/2015)... Thermage was the first to come out with ... 2007 coinciding with the release of NXT or CPT, the ... Aesthetics was the first practice in New York to debut ... results that had never been achieved before non-surgically. Even ... considered by many as the leading skin tightening device. ...
Breaking Medicine News(10 mins):Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the American Association of Nurse Practitioners’ 2015 National Conference 2Health News:Skin Expert Holly CaSaroll Announces New Cutting Edge Results with RadiessePlus Filler Available at Detroit Skin and Wellness Clinic 2Health News:Non-Surgical Fat Reduction and Skin Tightening Procedures, Thermage and Exilis, Increase 200% at Precision Aesthetics in New York, April 2015 2
... hospital ranked as one of Americas Best by U.S. News ... days than those admitted to a non-ranked hospital , according ... of Internal Medicine, one of the JAMA/Archives journals. ... mortality measures that are publicly reported by the Centers for ...
... eating uncooked fish dishes like koi-pla puts people in ... cause a type of liver cancer called cholangiocarcinoma ... weeks PLoS Medicine. ,Banchob Sripa (Khon Kaen ... food-borne trematode Opisthorchis viverrini (the SE Asian liver fluke) ...
... research, published in the July issue of the journal ... method for enhancing the potency and effectiveness of ... a variety of human cancers. , A ... human cancer cells to a promising treatment currently being ...
... According to a study published in the July 10, ... American Academy of Neurology , People with early Parkinsons ... of hallucinations, sleepiness, and swelling. ,By identifying ... for early intervention and possibly reduce disability, said study ...
... fashion designer Giorgio Armani's group said Wednesday it will open ... of both hot springs and high fashion. ... Ginza, one of Tokyo's ritziest districts, as part of its ... market. ,The 6,000 square-meter (65,000 square-foot) complex opening ...
... of British scientists claims they can soon release the worlds ... so, the NHS Trust of UK will stand to save billions ... most common neurological diseases in the western world, costs the NHS ... scientists, they have identified a series of proteins, which are most ...
Cached Medicine News:Health News:Americas Best Hospital Reduced Heart Attack Rates 2Health News:Americas Best Hospital Reduced Heart Attack Rates 3Health News:New Cancer Therapy in Clinical Trial 2Health News:Early Parkinsons Show Hallucination,sleepiness 2Health News:Simple Blood Test May Predict Alzheimers Disease 2
(Date:5/27/2015)... , May 27, 2015  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... Laboratories, will move its laboratory operations in ... Raleigh Durham , North Carolina.  Sequenom ... performed at the North Carolina ...
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: ... 2018 Summary GlobalData estimates that the ... market was approximately $179m across the 6MM covered ... are investing their attention, time, and financial resources ... of research and development (R&D) strategies. One notable ...
(Date:5/27/2015)... , May 27, 2015 Protein purification involves ... on differences in their physical properties. The objective of ... amount of functional protein with fewest contaminants. The global ... at a CAGR of around 5% to 6% during ... increased research in the pharmaceutical and biotechnological fields, growing ...
Breaking Medicine Technology:Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 2OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 4Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3
... Phase III Study Provides Further Evidence of,the ... the Treatment,of Rheumatoid Arthritis, BASEL, Switzerland, June ... second multinational phase III Actemra,(tocilizumab) study, successfully ... greater proportion of patients treated with Actemra,in ...
... Production Through Inhibition,of PDE-4 Enzyme, PALO ALTO, ... a privately held pharmaceutical company, announced,today the ... of,AN2728, a first-in-class topical therapy under investigation ... AN2728 to be,well-tolerated, with activity comparable to ...
Cached Medicine Technology:New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2
... Ultra thin collagen coated highly ... ultra thin wall construction offers ... The Hemacarotid UltraThin Patch provides ... conformability, and healing, without suture ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... EVS is engineered to close arteriotomies ... ergonomic stapler with a simple trigger ... A deliver sheath gently locks ... control of the site before, during, ...
Medicine Products: